30 mg lyophilised · single compound
$280.00 CAD
Retatrutide is a peptide that acts on three of the body's metabolic hormone receptors at once, making it a focus of metabolic research. Studies examine its combined effect on appetite- and energy-regulating pathways.
For laboratory and research use only - not for human consumption.
Checking the live COA archive for the newest lot documentation.
Use the verification archive to select a peptide name and review all published lot records alphabetically.
View previous lab resultsRetatrutide is a single peptide engineered to switch on three metabolic hormone receptors at once - GLP-1, GIP, and glucagon - earning it the nickname “triple agonist.” These receptors help govern appetite, insulin, and energy use.
It is in active clinical development. A 48-week Phase 2 trial in adults with obesity reported mean body-weight reductions of up to roughly 24% at the highest dose, with gastrointestinal side-effects typical of this drug class. It is studied in obesity, type-2-diabetes, and fatty-liver research.
Simultaneous agonism (activation) of the GLP-1, GIP, and glucagon receptors - combining reduced appetite, improved insulin response, and increased energy expenditure in models.
Retatrutide is investigational - it is in late-stage (Phase 3) clinical trials run by its pharmaceutical developer and is not approved by any regulatory authority. The material here is an unapproved research compound, not the trial medicine, and not for human consumption.
A single vial containing 30 mg of Retatrutide as a lyophilised powder.
